Skip to main content

LabCorp to Offer Ipsogen's JAK2 Leukemia Assay in US via CLIA Labs

NEW YORK (GenomeWeb News) - LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said today.
 
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights. 
 
The license will allow LabCorp to offer the test, which is registered as an IVD in Europe, through its CLIA-registered US labs.
 
The company said that a “high proportion” of individuals with myeloproliferative disorders have a dominant mutation of the JAK2 gene.
 
Financial terms of the agreement were not released.
 
Last month, Ispogen granted Warnex rights to offer the JAK2 assay in Canada.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.